Your Client Rank:
Loading...
99
Updated 22-May-2025
| Company | Sales | Gross M. | SGA % Sales | R&D % Sales | Trading M. | Tax Rate | Net Income | EPS |
| | | | | | | | |
| Ascendis | 49.5% | -0.3% | -25.9% | -30.0% | | | | |
| Lilly | 18.2% | 0.3% | -5.5% | -11.0% | 10.1% | -0.5% | 31.1% | 31.3% |
| Novo | 12.3% | -0.2% | -2.0% | -2.6% | 1.6% | 1.0% | 14.3% | 15.4% |
| Daiichi | 10.9% | 1.5% | 2.5% | -3.6% | 4.6% | 4.0% | 14.0% | 14.1% |
| Vertex | 10.3% | 0.8% | -0.9% | -18.1% | 52.9% | -26.0% | >100% | >100% |
| Eisai | 7.8% | -1.5% | -2.3% | -6.6% | 11.6% | 2.7% | 18.0% | 19.3% |
| Sanofi | 6.6% | 0.9% | -3.4% | -3.2% | 5.1% | 0.8% | 10.6% | 11.2% |
| AbbVie | 6.3% | 0.1% | -3.6% | -6.4% | 4.6% | -2.0% | 12.6% | 12.6% |
| Astra | 5.1% | 0.4% | -0.9% | 0.0% | 4.9% | 0.8% | 9.4% | 9.5% |
| Regeneron | 5.0% | 0.1% | -1.3% | -0.7% | 1.7% | 7.4% | 4.8% | 5.3% |
| Chugai | 4.6% | 1.3% | -2.6% | -1.4% | 3.1% | -1.7% | 9.9% | 9.2% |
| Roche | 4.4% | 0.2% | -1.3% | -1.4% | 1.8% | 2.7% | 6.7% | 6.6% |
| JNJ | 4.1% | -0.4% | -1.4% | -4.1% | 2.5% | 0.5% | 5.4% | 6.2% |
| Novartis | 3.4% | 0.1% | -1.3% | 0.3% | 1.6% | 0.6% | 5.2% | 6.4% |
| Gilead | 3.3% | -0.2% | -2.5% | -11.6% | 10.0% | -6.3% | 17.4% | 17.3% |
| Teva | 3.3% | 1.5% | -6.0% | 0.1% | 3.4% | 3.0% | 9.4% | 8.2% |
| Amgen | 3.0% | -0.1% | -1.5% | 2.5% | -1.2% | 1.6% | 3.5% | 3.6% |
| Merck | 2.6% | -0.1% | -0.9% | -4.5% | 2.3% | 0.0% | 5.7% | 6.7% |
| Glaxo | 1.9% | -0.2% | 0.8% | 1.5% | 1.4% | 0.3% | 4.3% | 3.7% |
| Bayer | 1.6% | 1.6% | -2.1% | -1.3% | 16.8% | | 4.4% | 4.3% |
| Takeda | 1.3% | 0.4% | -1.0% | 0.7% | 17.0% | -9.2% | 2.9% | 5.5% |
| Lundbeck | 1.0% | 0.1% | -0.9% | 3.3% | 0.8% | 6.9% | 0.0% | -3.0% |
| Shionogi | -0.1% | -1.1% | 1.4% | 1.0% | -4.7% | 5.5% | -5.0% | -3.8% |
| Biogen | -0.6% | 0.4% | -0.2% | 0.3% | 0.9% | 2.5% | 0.9% | 1.2% |
| Astellas | -3.4% | -0.7% | -2.4% | 2.3% | 0.9% | -5.8% | -0.7% | -0.8% |
| Pfizer | -3.4% | 0.0% | -0.2% | 2.6% | -1.5% | 1.3% | -5.0% | -5.0% |
| Bristol | -5.2% | 0.3% | 1.3% | -13.5% | 28.1% | -20.5% | 36.3% | 36.9% |
| Neurocrine | | | | | | | | |
| EU Major | 5.1% | 0.5% | -1.8% | -1.0% | 3.9% | 0.8% | 8.4% | 8.1% |
| Other EU | 11.9% | 0.5% | -8.5% | -6.7% | 47.3% | -24.8% | >100% | |
| US Major | 4.3% | 0.2% | -2.2% | -7.0% | 6.1% | -2.1% | 11.3% | 17.6% |
| US Big Biotech | 4.0% | 0.2% | -2.1% | -6.5% | 5.7% | -2.5% | 12.0% | 10.2% |
| Other US | 3.3% | 1.5% | -6.0% | 0.1% | 3.4% | 3.0% | 9.4% | 8.2% |
| Japanese | 3.4% | 0.5% | -0.1% | -0.7% | 6.2% | -1.2% | 5.8% | 7.5% |
